Jiachen Xu

2.1k total citations · 1 hit paper
51 papers, 1.0k citations indexed

About

Jiachen Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jiachen Xu has authored 51 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Jiachen Xu's work include Cancer Immunotherapy and Biomarkers (23 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Research Studies (8 papers). Jiachen Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Lung Cancer Treatments and Mutations (19 papers) and Lung Cancer Research Studies (8 papers). Jiachen Xu collaborates with scholars based in China, United States and Sweden. Jiachen Xu's co-authors include Zhijie Wang, Jie Wang, Jie He, Kailun Fei, Hua Bai, Zhenlin Yang, Yibo Gao, Jianchun Duan, Fengwei Tan and Rui Wan and has published in prestigious journals such as Advanced Materials, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Jiachen Xu

48 papers receiving 996 citations

Hit Papers

Treatment-related adverse events of PD-1 and PD-L1 inhibi... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
    2021 160 citations Hua Bai, Jianchun Duan et al. profile →

Peers

Jiachen Xu
Jianchun Duan China
Changsong Qi China
Laure Favier France
Muhammad Khan China
Ewa Kalinka‐Warzocha Poland
Preston D. Steen United States
Etienne Giroux‐Leprieur France
Riki Okita Japan
Jianchun Duan China
Jiachen Xu
Citations per year, relative to Jiachen Xu Jiachen Xu (= 1×) peers Jianchun Duan

Countries citing papers authored by Jiachen Xu

Since Specialization
Citations

This map shows the geographic impact of Jiachen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiachen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiachen Xu more than expected).

Fields of papers citing papers by Jiachen Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiachen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiachen Xu. The network helps show where Jiachen Xu may publish in the future.

Co-authorship network of co-authors of Jiachen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiachen Xu. A scholar is included among the top collaborators of Jiachen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiachen Xu. Jiachen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Qinyan, Shiqi Liang, Jinfu Qian, et al.. (2024). OTUD1 promotes isoprenaline- and myocardial infarction-induced heart failure by targeting PDE5A in cardiomyocytes. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(4). 167018–167018. 12 indexed citations
2.
Yang, Zhenlin, Bolun Zhou, Wei Guo, et al.. (2024). Genomic characteristics and immune landscape of super multiple primary lung cancer. EBioMedicine. 101. 105019–105019. 6 indexed citations
3.
Zhu, Weiwei, Qianhui Zhang, Minxiu Wang, et al.. (2024). Compound SJ-12 attenuates streptozocin-induced diabetic cardiomyopathy by stabilizing SERCA2a. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(5). 167140–167140. 4 indexed citations
4.
Zhou, Yangzhong, Bing Xu, Jiuliang Zhao, et al.. (2024). Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. Journal for ImmunoTherapy of Cancer. 12(1). e007959–e007959. 5 indexed citations
5.
Zhao, Jie, Jiachen Xu, Tian Qiu, Jie Wang, & Zhijie Wang. (2024). Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib. SHILAP Revista de lepidopterología. 16(1). 7–7.
6.
Han, Jiefei, Alexandre Reuben, Jianjun Zhang, et al.. (2024). Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature Communications. 15(1). 1199–1199. 7 indexed citations
7.
Han, Jibo, Liming Lin, Bozhi Ye, et al.. (2024). Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21. Theranostics. 14(16). 6236–6248. 11 indexed citations
8.
Liang, Shiqi, Jiachen Xu, Wu Luo, et al.. (2023). Isoproterenol induces MD2 activation by β-AR-cAMP-PKA-ROS signalling axis in cardiomyocytes and macrophages drives inflammatory heart failure. Acta Pharmacologica Sinica. 45(3). 531–544. 21 indexed citations
9.
Sun, Boyang, Tian Qiu, Jianchun Duan, et al.. (2023). Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors. Cancer Research Communications. 3(4). 532–539. 7 indexed citations
10.
Wang, Yalong, Zhenlin Yang, Ping Chen, et al.. (2023). Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis. Cancer Gene Therapy. 2 indexed citations
11.
Liu, Lihui, Sini Li, Yan Qu, et al.. (2023). Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Reports Medicine. 4(10). 101206–101206. 30 indexed citations
12.
Wang, Lu, et al.. (2023). Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer. Frontiers in Immunology. 14. 1265865–1265865. 12 indexed citations
13.
Xu, Jiachen, Qinyan Wang, Xue Han, et al.. (2023). 20(S)-ginsenoside Rh2 inhibits angiotensin-2 mediated cardiac remodeling and inflammation associated with suppression of the JNK/AP-1 pathway. Biomedicine & Pharmacotherapy. 169. 115880–115880. 12 indexed citations
14.
Bai, Guangyu, Zhenlin Yang, Ping Chen, et al.. (2023). Multiple primary lung cancer: Updates of clinical management and genomic features. Frontiers in Oncology. 13. 1034752–1034752. 11 indexed citations
15.
Yan, Guangjian, et al.. (2022). Human Activity Changes During COVID‐19 Lockdown in China—A View From Nighttime Light. GeoHealth. 6(8). e2021GH000555–e2021GH000555. 9 indexed citations
16.
Zhang, Qiaoxia, et al.. (2022). Identifying susceptibility genes for essential hypertension by transcriptome-wide association study. Biochemistry and Biophysics Reports. 32. 101387–101387. 6 indexed citations
17.
Xu, Jiachen, et al.. (2022). MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. Molecular Diagnosis & Therapy. 26(2). 203–227. 47 indexed citations
18.
Zhao, Jie, Hua Bai, Jianchun Duan, et al.. (2021). Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis. SHILAP Revista de lepidopterología. 2(1). 41–49. 3 indexed citations
19.
20.
Tian, Yanhua, Jiachen Xu, Qian Chu, et al.. (2020). A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine. 18(1). 232–232. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianchun Duan Breakdown of academic impact, for papers by Changsong Qi Breakdown of academic impact, for papers by Laure Favier Breakdown of academic impact, for papers by Muhammad Khan Breakdown of academic impact, for papers by Ewa Kalinka‐Warzocha Breakdown of academic impact, for papers by Preston D. Steen Breakdown of academic impact, for papers by Etienne Giroux‐Leprieur Breakdown of academic impact, for papers by Riki Okita
Rankless by CCL
2026